NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process
September 25, 2018Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing
Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …
President Trump pledges to fight drug addiction at UN meeting
September 25, 2018Manufacturing and Production Trump, UN, drugs, illicit drugs, trafficking
President Donald Trump has pledged to fight “the scourge of drug addiction,” as he outlined his commitment to the fight …
Roche’s entrectinib shrinks lung tumours with two-year response duration
September 25, 2018Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib
Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …
J&J pledges to end global TB pandemic
September 25, 2018Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis
Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s …
Novartis cuts more than 2500 jobs in Switzerland and the UK
September 25, 2018Manufacturing and Production Basel, Jobs, Novartis, Switzerland, grimsby, manufacturing
Swiss multinational Novartis are set to cut thousands of jobs across Europe in an effort to boost profitability. The move …
AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer
September 25, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma
AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …
Working Life: Jean-Christophe Tellier, CEO of UCB Pharma
September 24, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB, Working Life, feature
Just as his company announced robust H1 2018 financials, UCB’s Jean-Christophe Tellier spoke to Pharmafocus to share his experiences of …
HIV on the rise among straight men in Australia
September 24, 2018Medical Communications, Sales and Marketing AIDS, Aboriginal, Australia, HIV, Kirby Institute
The number of new HIV diagnoses is on the rise among heterosexual men in Australia, according to a new report …
Sarepta’s Exondys 51 hit with negative CHMP opinion in Duchenne muscular dystrophy
September 24, 2018Research and Development, Sales and Marketing CHMP, Duchenne Muscular Dystophy, EMA, Europe, Exondys 51, pharma, sarepta
Sarepta Therapeutics has been rocked by a hurdle in its pursuit of regulatory approval in Europe, as the company revealed …
Courts back NHS in fight against Novartis and Bayer
September 24, 2018Sales and Marketing Bayer, Eylea, NHS, Novartis, avastin, ludentis
The NHS has won a court case against multinational pharmaceutical firms Novartis and Bayer, after the companies sought to block …
Life expectancy falls in America; drugs, alcohol and suicide to blame
September 24, 2018Sales and Marketing USA, alcohol, drugs, health, opiod crisis, suicide
Life expectancy has fallen for the second year in a row for people in the United States, according to new …
AstraZeneca’s Farxiga cuts heart risk in type 2 diabetes patients
September 24, 2018Research and Development, Sales and Marketing AstraZeneca, diabetes, farxiga, pharma
AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings …
EU approval for Mylan and Fujifilm’s Humira biosimilar
September 21, 2018Medical Communications, Sales and Marketing EU, Europe, Humira, Mylan, biosimilar, pharma
The European Commission has approved its fifth biosimilar of the world’s best-selling drug, Abbvie’s Humira (adalimumab), granting marketing authorisation to …
Top Ten most popular articles on Pharmafile.com this week
September 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Novartis, Novo Nordisk, Senate, UCB, manufacturing, opioid crisis, top 10
Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move …
ABPI forges five year partnership with AHSN focused on increased uptake of transformative biomedical innovations into the NHS
September 21, 2018Medical Communications ABPI, NHS, UK, ahsn, collaboration
The Association of the British Pharmaceutical Industry (ABPI) has announced that it is forging a five year partnership with the …
British MPs call for HIV prevention PrEP drugs to be made available on NHS in England
September 21, 2018Medical Communications
PrEP drugs – pre-sex drugs that are able to dramatically reduce the chances a person has of contracting HIV – …
Surgeon General calls for cultural shift in approach to opioid crisis
September 21, 2018Medical Communications Trump, US, opioid crisis, opioid epidemic, surgeon general
The Surgeon General of the United States has called for a cultural shift in the way in which Americans talk …
Shares in Molecular Templates surge after the announcement of Takeda collaboration
September 20, 2018Business Services, Research and Development Molecular Templates, Shares, Takeda, markets, stocks
Shares in the Texas based biotech Molecular Templates have soared after the company announced that they would be collaborating with …
A goal in mind: Transforming the way Alzheimer’s disease is diagnosed and treated
September 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Roche, pharma
Dr Rachelle Doody, Global Head of Neurodegeneration at Roche/Genentech, discusses key learnings from clinical trials in Alzheimer’s disease, and how …
Astellas’ chronic kidney drug shows superiority at Phase 3
September 20, 2018Research and Development Astellas, chronic kidney disease, pharma, roxadustat
Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
